Unveiling the hidden role of SDHA in breast cancer proliferation: a novel therapeutic avenue

被引:0
|
作者
Yong, Liyun [1 ]
Fang, Yuan [1 ]
Jin, Lingli [1 ]
Zhang, Xiuqin [2 ]
Luis, Manuel A. [1 ]
Lin, Xiaoyan [3 ]
Tang, Shasha [1 ]
Cai, Fengfeng [1 ]
机构
[1] Tongji Univ, Tongji Hosp, Sch Med, Dept Breast Surg, 389 Xincun Rd, Shanghai 200065, Peoples R China
[2] Tongji Univ, Tongji Hosp, Sch Med, Dept Pathol, 389 Xincun Rd, Shanghai 200065, Peoples R China
[3] Tongji Univ, Yangpu Hosp, Sch Med, Dept Breast Surg, Shanghai 200090, Peoples R China
关键词
Breast cancer; SDHA; Prognosis; Proliferation; Migration; MITOCHONDRIAL COMPLEX II; SUCCINATE-DEHYDROGENASE; GENE-MUTATIONS; HETEROGENEITY; EXPRESSION; BIOMARKERS; CELLS;
D O I
10.1186/s12935-025-03746-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundWe observed an increased presence of succinate dehydrogenase complex subunit A (SDHA), a mitochondrial enzyme, in breast cancer (BC), which contributes to its proliferation. While SDHA deficiency has been extensively researched in rare disorders, the upregulation of SDHA and its impact on BC remain understudied. The aim of this study is to investigate the role of SDHA in BC.MethodsThe mRNA expression of SDHA was analyzed from TCGA, clinical BC tissues and various BC cell lines via qPCR. Immunohistochemistry was also applied to detect the SDHA expression. Our study investigated the functional outcomes of SDHA overexpression and knockdown in BC utilizing clinical BC tissues from patients and various BC cell lines (MDA-MB-453, MDA-MB-468, SKBR3, and MCF-7). Multiple web platforms and software tools, including R, HPA and TISIDB, were employed to perform comprehensive data analysis. SDHA overexpression and siSDHA were transiently transfected into the cancer cells separately to assess expression levels, cellular proliferation, and migration dynamics through colony formation assay, CCK8 assay, wound-healing analysis.ResultsWe found that the mRNA expression level of SDHA was higher in cancer tissues or cells than in non-cancerous tissues or mammary epithelial cell in TCGA dataset, BC clinical specimens and BC cell lines, respectively. High SDHA expression was associated with poor overall survival (OS, p = 0.016) and disease specific survival (DSS, p = 0.024) in BC patients. Besides, our findings revealed MDA-MB-468, SKBR3 and MCF-7 cells transfected with siSDHA exhibited significantly reduced proliferation and migration capabilities. Conversely, the proliferation and migration abilities of these BC cells significantly increased when transfected with SDHA overexpression.ConclusionsIn conclusion, this study highlights the previously underestimated role of SDHA in BC proliferation, presenting a novel avenue for therapeutic intervention.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
    Messaoudene, M.
    Mourikis, T. P.
    Michels, J.
    Fu, Y.
    Bonvalet, M.
    Lacroix-Trikki, M.
    Routy, B.
    Fluckiger, A.
    Rusakiewicz, S.
    Roberti, M. P.
    Cotteret, S.
    Flament, C.
    Poirier-Colame, V
    Jacquelot, N.
    Ghiringhelli, F.
    Caignard, A.
    Eggermont, A. M. M.
    Kroemer, G.
    Marabelle, A.
    Arnedos, M.
    Vicier, C.
    Dogan, S.
    Jaulin, F.
    Sammut, S-J
    Cope, W.
    Caldas, C.
    Delaloge, S.
    McGranahan, N.
    Andre, F.
    Zitvogel, L.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 934 - 944
  • [32] The Role of DLLs in Cancer: A Novel Therapeutic Target
    Xiu, Meng-Xi
    Liu, Yuan-Meng
    Kuang, Bo-hai
    ONCOTARGETS AND THERAPY, 2020, 13 : 3881 - 3901
  • [33] Breast Cancer Stem Cells: A Novel Therapeutic Target
    Gangopadhyay, Sudeshna
    Nandy, Argha
    Hor, Pooja
    Mukhopadhyay, Ashis
    CLINICAL BREAST CANCER, 2013, 13 (01) : 7 - 15
  • [34] Identification of novel genetic/therapeutic vulnerabilities in breast cancer
    Wang, Xiyin
    Emch, Michael
    Voll, Lauren
    Russell, Rebecca
    Rodman, Esther
    Beer, Philip
    Hawse, John
    CANCER RESEARCH, 2024, 84 (09)
  • [35] BET inhibitors as novel therapeutic agents in breast cancer
    Ocana, Alberto
    Nieto-Jimenez, Cristina
    Pandiella, Atanasio
    ONCOTARGET, 2017, 8 (41) : 71285 - 71291
  • [36] Arginine methyltransferases as novel therapeutic targets for breast cancer
    Morettin, Alan
    Baldwin, R. Mitchell
    Cote, Jocelyn
    MUTAGENESIS, 2015, 30 (02) : 177 - 189
  • [37] A novel therapeutic to enhance the immunogenicity of breast cancer cells
    Vishnubhotla, Priya
    Khaled, Amr
    Showalter, Anne
    Oyer, Jeremiah
    Igarshi, Robert
    Copik, Alicja
    Khalid, Annette
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [38] Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer
    Oh, Sumin
    Ko, Je Yeong
    Oh, Chaeun
    Yoo, Kyung Hyun
    TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 287 - 313
  • [39] Novel therapeutic approaches to the treatment of metastatic breast cancer
    Fernandez, Yolanda
    Cueva, Juan
    Palomo, Andres G.
    Ramos, Manuel
    de Juan, Ana
    Calvo, Lourdes
    Garcia-Mata, Jesus
    Garcia-Teijido, Paula
    Pelaez, Ignacio
    Garcia-Estevez, Laura
    CANCER TREATMENT REVIEWS, 2010, 36 (01) : 33 - 42
  • [40] A novel therapeutic approach for triple negative breast cancer
    Boopalan, Thiyagarajan
    Arumugam, Arunkumar
    Suman, Suman
    Das, Trinath P.
    Damodaran, Chendil
    Lakshmanaswamy, Rajkumar
    CANCER RESEARCH, 2012, 72